Exploring the selective mechanism of inhibitors towards different subtypes of class I PI3K

被引:1
|
作者
Fang, Xiaoniu [1 ]
Gao, Ya [1 ]
Wang, Chen [1 ]
Chen, Huimin [1 ]
Zhu, Tong [2 ]
机构
[1] Shanghai Univ Engn Sci, Sch Math Phys & Stat, Shanghai 201620, Peoples R China
[2] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China
基金
中国国家自然科学基金;
关键词
Phosphoinositide; 3-kinase; Molecular dynamics simulation; Binding free energy; Selectivity; MOLECULAR-DYNAMICS SIMULATIONS; PARTICLE MESH EWALD; PI3K/AKT/MTOR PATHWAY; AMBER; DISCOVERY; IDENTIFICATION; MUTATIONS; DOCKING;
D O I
10.1016/j.cplett.2021.139174
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The activation of the PI3K signaling pathway is closely related to the formation of various cancers. However, four subtypes of PI3K have a high degree of sequence homology, which is challenging to develop isomeric selective inhibitors. In this work, MD simulations and binding affinity calculations are combined to elucidate the interaction mechanism of different inhibitors towards PI3K subtypes. Key residues, hydrophobic interactions, and hydrogen bonds forming between the receptor and inhibitor are pointed out, which is critical to the understanding of the binding selectivity. This work can provide a theoretical reference for the design of more promising selective inhibitors.
引用
下载
收藏
页数:6
相关论文
共 50 条
  • [1] Quinalozinones as Inhibitors of Class I PI3K Kinases
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (01): : 15 - 16
  • [2] Discovery of novel class of alpha selective PI3K inhibitors
    Garland, Keira
    Hanan, Emily
    Staben, Steven
    Braun, Marie-Gabrielle
    Edgar, Kyle
    Endres, Nick
    Friedman, Lori
    Nguyen, Amanda
    Pang, Jodie
    Purkey, Hans
    Salphati, Laurent
    Schmidt, Stephen
    Song, Kyung
    Ultsch, Mark
    Jaochico, Allan
    Chan, Connie
    Eigenbrot, Charles
    MacLeod, Calum
    Jackson, Philip
    Narukulla, Raman
    Knight, Jamie
    Yeap, Kuen
    Messick, Kristen
    Valle, Nicole
    Heald, Robert
    Nannini, Michelle
    Hamilton, Pat
    Clausen, Saundra
    Young, Amy
    Sampath, Deepak
    Hong, Rebecca
    Lee, Man-Ling
    Blench, Toby
    Elliott, Richard
    Lu, Aijun
    Gu, Xiao-Hu
    Xin, Jianfeng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [3] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2012, 72
  • [4] Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors
    Spoerke, Jill
    Desai, Rupal
    Patel, Rajesh
    Fredrickson, Jill
    Wang, Yulei
    Levy, Gallia
    Gendreau, Steve
    Lauchle, Jennifer
    Derynck, Mika
    Raja, Rajiv
    Koeppen, Hartmut
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2013, 73 (08)
  • [5] Designing selective PI3K inhibitors
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2010, 9 : 105 - 105
  • [6] Designing selective PI3K inhibitors
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
  • [7] A class of highly selective inhibitors bind to an active state of PI3Kγ
    Gangadhara, Gangadhara
    Dahl, Goran
    Bohnacker, Thomas
    Rae, Rebecca
    Gunnarsson, Jenny
    Blaho, Stefan
    Oster, Linda
    Lindmark, Helena
    Karabelas, Kostas
    Pemberton, Nils
    Tyrchan, Christian
    Mogemark, Mickael
    Wymann, Matthias P.
    Williams, Roger L.
    Perry, Matthew W. D.
    Papavoine, Tineke
    Petersen, Jens
    NATURE CHEMICAL BIOLOGY, 2019, 15 (04) : 348 - +
  • [8] A class of highly selective inhibitors bind to an active state of PI3Kγ
    Gangadhara Gangadhara
    Göran Dahl
    Thomas Bohnacker
    Rebecca Rae
    Jenny Gunnarsson
    Stefan Blaho
    Linda Öster
    Helena Lindmark
    Kostas Karabelas
    Nils Pemberton
    Christian Tyrchan
    Mickael Mogemark
    Matthias P. Wymann
    Roger L. Williams
    Matthew W. D. Perry
    Tineke Papavoine
    Jens Petersen
    Nature Chemical Biology, 2019, 15 : 348 - 357
  • [9] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Nakanishi, Yoshito
    Spoerke, Jill M.
    Derynck, Mika
    Lauchle, Jennifer O.
    Koeppen, Hartmut
    Fredrickson, Jill
    Ware, Joseph
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [10] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257